乳腺癌筛查:美国预防服务工作组证据报告与系统综述
本系统综述为美国预防服务工作组评估不同乳腺癌筛查策略,纳入7项随机临床试验和13项非随机研究。比较不同年龄、间隔和模式(如数字乳腺断层合成、磁共振、超声补充筛查)对死亡率、晚期癌症检出和筛查危害的影响。证据显示数字乳腺断层合成较数字乳腺摄影检出更多浸润癌但间隔癌无显著差异,磁共振补充筛查降低间隔癌风险但增加假阳性,总体证据不足以确定最佳策略。
要点
- 数字乳腺断层合成较数字乳腺摄影首次筛查检出更多浸润癌,间隔癌无显著差异。
- 磁共振补充筛查致密乳腺者降低间隔癌风险但增加假阳性召回和活检。
- 比较不同筛查策略有效性的证据尚不明确,关键研究未完成。
核心结论
- 比较不同乳腺癌筛查策略有效性的证据尚不明确,因关键研究尚未完成且报告分期迁移或死亡率结局的研究很少。
研究设计与样本
- 系统综述纳入7项随机临床试验和13项非随机研究,由两名评价员独立评估研究合格性和质量,提取中高质量研究数据。
主要发现
- 一项非随机试验模拟研究估计74岁以上筛查无死亡率差异(校正风险比1.00 [95%CI 0.83-1.19])。
- 数字乳腺断层合成较数字乳腺摄影首次筛查检出更多浸润癌,间隔癌无统计学显著差异(合并相对危险度0.87 [95%CI 0.64-1.17];3项研究[n=130 196];I²=0%)。
- 随机对照试验将致密乳腺者随机邀请接受磁共振补充筛查,报告间隔癌风险降低(相对危险度0.47 [95%CI 0.29-0.77]),但干预组额外假阳性召回和活检结果增加。
- 一项随机对照试验和一项非随机研究补充超声筛查报告额外假阳性,间隔癌无差异。
- 数字乳腺断层合成较数字乳腺摄影在后续筛查轮次中晚期癌症(II期或更高)风险在个别试验中无统计学显著差异,有限证据提示数字乳腺断层合成召回率较低。
局限性
- 关键研究尚未完成,且报告分期迁移或死亡率结局的研究很少,导致证据不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Breast cancer is a leading cause of cancer mortality for US women. Trials have established that screening mammography can reduce mortality risk, but optimal screening ages, intervals, and modalities for population screening guidelines remain unclear. OBJECTIVE: To review studies comparing different breast cancer screening strategies for the US Preventive Services Task Force. DATA SOURCES: MEDLINE, Cochrane Library through August 22, 2022; literature surveillance through March 2024. STUDY SELECTION: English-language publications; randomized clinical trials and nonrandomized studies comparing screening strategies; expanded criteria for screening harms. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently assessed study eligibility and quality; data extracted from fair- and good-quality studies. MAIN OUTCOMES AND MEASURES: Mortality, morbidity, progression to advanced cancer, interval cancers, screening harms. RESULTS: Seven randomized clinical trials and 13 nonrandomized studies were included; 2 nonrandomized studies reported mortality outcomes. A nonrandomized trial emulation study estimated no mortality difference for screening beyond age 74 years (adjusted hazard ratio, 1.00 [95% CI, 0.83 to 1.19]). Advanced cancer detection did not differ following annual or biennial screening intervals in a nonrandomized study. Three trials compared digital breast tomosynthesis (DBT) mammography screening with digital mammography alone. With DBT, more invasive cancers were detected at the first screening round than with digital mammography, but there were no statistically significant differences in interval cancers (pooled relative risk, 0.87 [95% CI, 0.64-1.17]; 3 studies [n = 130 196]; I2 = 0%). Risk of advanced cancer (stage II or higher) at the subsequent screening round was not statistically significant for DBT vs digital mammography in the individual trials. Limited evidence from trials and nonrandomized studies suggested lower recall rates with DBT. An RCT randomizing individuals with dense breasts to invitations for supplemental screening with magnetic resonance imaging reported reduced interval cancer risk (relative risk, 0.47 [95% CI, 0.29-0.77]) and additional false-positive recalls and biopsy results with the intervention; no longer-term advanced breast cancer incidence or morbidity and mortality outcomes were available. One RCT and 1 nonrandomized study of supplemental ultrasound screening reported additional false-positives and no differences in interval cancers. CONCLUSIONS AND RELEVANCE: Evidence comparing the effectiveness of different breast cancer screening strategies is inconclusive because key studies have not yet been completed and few studies have reported the stage shift or mortality outcomes necessary to assess relative benefits.
引用
- Henderson JT, Webber EM, Weyrich MS, et al. Screening for Breast Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2024. PMID: 38687490. doi:10.1001/jama.2023.25844
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。